TOLERANZIA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.492 SEK | -3.53% |
|
+0.41% | +14.95% |
| Feb. 23 | Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 23 | Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 27.59M 2.53M | Sales 2022 | 35.37M 3.24M | Capitalization | 124M 11.32M |
|---|---|---|---|---|---|
| Net income 2021 | -6M -550K | Net income 2022 | -8M -733K | EV / Sales 2021 | 1.98 x |
| Net cash position 2021 | 75.43M 6.91M | Net cash position 2022 | 33.09M 3.03M | EV / Sales 2022 | 2.56 x |
| P/E ratio 2021 |
-13.3
x | P/E ratio 2022 |
-14.6
x | Employees | 12 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 82.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.94% | ||
| 1 week | +7.82% | ||
| Current month | -5.20% | ||
| 1 month | +22.30% | ||
| 3 months | -4.49% | ||
| 6 months | +2.20% | ||
| Current year | +19.16% |
1 week
0.45
0.54
1 month
0.370.58
Current year
0.370.66
1 year
0.351.03
3 years
0.352.07
5 years
0.357.76
10 years
0.3512.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | - | |
Thomas Pålsson
DFI | Director of Finance/CFO | 72 | 23-10-29 |
| Chief Tech/Sci/R&D Officer | 65 | 18-01-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 19-12-31 | |
Thomas Eldered
BRD | Director/Board Member | 64 | 20-12-31 |
Maarten Kraan
BRD | Director/Board Member | 63 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 0.492 | -3.53% | 9 800 |
| 24-04-15 | 0.51 | +4.94% | 75,879 |
| 24-04-12 | 0.486 | -0.21% | 62,333 |
| 24-04-11 | 0.487 | -1.62% | 36,570 |
| 24-04-10 | 0.495 | +1.02% | 397,445 |
Delayed Quote Nasdaq Stockholm, April 15, 2024 at 10:34 am EDT
More quotes
Toleranzia AB is a Sweden-based company engaged in the development of a platform technology for treatment of autoimmune diseases. The Company's main project is aimed against an autoimmune nerve-muscle disease and myasthenia gravis. The Company's platform technology enables the development of therapies targeting the cause of the disease, which in the current situation is the usual treatment.
Calendar
2024-05-19
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +19.16% | 8.79M | |
| +4.73% | 33.36B | |
| +7.47% | 7.27B | |
| +16.72% | 3.62B | |
| -8.27% | 3.43B | |
| -28.57% | 1.25B | |
| -34.80% | 1.14B | |
| +2.12% | 930M | |
| -41.53% | 866M | |
| -28.41% | 829M |
- Stock Market
- Equities
- TOL Stock
